1.14

4.20% -0.05

Cellectar Biosciences Inc (CLRB)

Overview News Price History Financials Discussions Forecast Stock Split

Cellectar Biosciences Inc stock is traded at $1.14, with a volume of 338.87K. It is down -4.20% in the last 24 hours and down -51.49% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Previous Close:

$1.19

Open:

$1.19

24h Volume:

338.87K

Relative Volume:

1.40

Market Cap:

$10.78M

Revenue:

Net Income/Loss:

$-20.84M

P/E Ratio:

-0.1546

EPS:

-7.3739

Net Cash Flow:

$-18.59M

1W Performance:

-21.38%

1M Performance:

-51.49%

6M Performance:

-62.13%

1Y Performance:

-76.00%

1-Day Range:

$1.12

$1.28

1-Week Range:

$1.12

$1.60

52-Week Range:

$1.12

$5.069

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name

Cellectar Biosciences Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(608) 441-8120

Address

100 CAMPUS DRIVE, FLORHAM PARK, NJ

Employee

Twitter

@CellectarBio

Next Earnings Date

2026-11-12

Latest SEC Filings

CLRB's Discussions on Twitter

Compare CLRB vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLRB Cellectar Biosciences Inc	1.14	10.78M	0	-20.84M	-18.59M	-7.3739
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-26	Initiated	Ladenburg Thalmann	Buy
Mar-10-26	Upgrade	Maxim Group	Hold → Buy
Dec-05-24	Resumed	Ladenburg Thalmann	Buy
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy

View All

Cellectar Biosciences Inc Stock (CLRB) Latest News

Oct 15, 2026

Cancer treatment responses lasted a median 16 months in Cellectar's study - Stock Titan

Oct 15, 2026

Cellectar Biosciences Presents Compelling Efficacy Data - GlobeNewswire

Oct 15, 2026

Oct 13, 2026

Cellectar Biosciences Share PriceCLRB, RNS News, Articles, Quotes, & Charts (NASDAQ:CLRB) - Proactive financial news

Oct 13, 2026

Sep 29, 2026

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia - Investing News Network

Sep 29, 2026

A cancer drug produced responses in 87.5% of patients resistant to a prior cancer treatment - Stock Titan

Sep 29, 2026

Cellectar Biosciences to Present Compelling Efficacy Data - GlobeNewswire

Sep 29, 2026

Sep 03, 2026

Cellectar Biosciences (CLRB) Edges Lower: Support Holds Near $2.41 Amid ConsolidationWeekly Profile - dars.gov.et

Sep 03, 2026

Cellectar Biosciences (CLRB) Edges Lower: Support Holds Near $2.41 Amid ConsolidationFibonacci Fan - dars.gov.et

Sep 03, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Initiates New Position in Cellect - GuruFocus

Aug 20, 2026

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 20, 2026

Aug 18, 2026